Brain Metastases, Adult Clinical Trial
— COIMBRAOfficial title:
The Cohort for Patient-reported Outcomes, Imaging and Trial Inclusion in Metastatic BRAin Disease (COIMBRA)
NCT number | NCT05267158 |
Other study ID # | NL67206.041.18 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 26, 2019 |
Est. completion date | May 1, 2026 |
The incidence of brain metastases is expected to increase because of better treatments of primary tumours. Novel diagnostic and therapeutic techniques are continuously being developed, all of which need thorough evaluation before they can be implemented in clinical routine. Randomized Controlled Trials are the gold standard to do so, but they have shown many challenges, especially when applied in a cancer setting. .The 'cohort multiple Randomized Controlled Trial (cmRCT)' design is a promising design for multiple (simultaneous) randomized evaluations of experimental interventions, with potential for increased recruitment, comparability and long-term outcomes as a standard. This design will speed up the process of translating treatment innovations to the daily clinic.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | May 1, 2026 |
Est. primary completion date | May 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years; - Either radiographic and/or histologic proof of metastatic brain disease, or eligible for prophylactic cranial irradiation; - Referred to the Department of Radiotherapy for cranial irradiation. Exclusion Criteria: - Mental disorder or cognitive dysfunction that hinder the patient's ability to understand the informed consent procedure and/or study details; - Patients with severe psychiatric disorders; - Inability to understand the Dutch language. |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Utrecht | Utrecht |
Lead Sponsor | Collaborator |
---|---|
UMC Utrecht |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | Survival of participating patients will be recorded using the follow up questionnaires (returned by family members) or are derived from the Municipal Personal Records Database (in Dutch: Basisregistratie Personen (BRP)) | Through study completion, an average of 1 year | |
Primary | Time and Type of re-intervention | Re-intervention (re-irradiation, surgery, other); Development of neurological symptoms; Development of new metastases. | Through study completion, an average of 1 year | |
Primary | Change in toxicity after radiotherapy | The toxicity will be reported by using the serious adverse event (SAE) questionnaire, every 6 months | Through study completion, an average of 1 year | |
Primary | Technical and treatment data | Dose, fractions and technique of radiotherapy. All other planned and/or received treatment for brain metastases and primary tumour (i.e. systemic therapy, surgery, radiotherapy), and the characteristics there of (type, dose, duration, awake surgery, extent of surgery, complications)
- Use of epileptic drugs, including type and dose |
Through study completion, an average of 1 year | |
Secondary | Change in patient reported outcomes; general quality of life | General quality of life will be reported by the questionnaires named C30 and EQ-5D. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the instrument most frequently used to measure quality of life in cancer patients, whereas the EQ-5D is widely used to measure and evaluate general health status.
Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy is completed. Both the total score of the questionnaires and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Change in patient reported outcomes; cancer related fatigue | Cancer related fatigue is measured by using the MFI-20 questionnaire. The MFI-20 is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: general fatigue, physical fatigue, reduced activity, reduced motivation and mental fatigue. The instrument was used in a Dutch and Scottish sample of cancer patients receiving radiotherapy
Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy is completed. Both the total score of the questionnaires and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Change in patient reported outcomes; depression and anxiety | Cancer related depression and anxiety is reported by the HADS. The Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire that has been found to be a reliable instrument for detecting states of anxiety and depression in the setting of hospital outpatient clinic. The HADS questionnaire has seven items each for depression and anxiety subscales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy is completed. Both the total score of the questionnaire and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Change in patient reported outcomes; disease-specific symptoms of brain metastases and (adverse) effects of their treatment | Disease-specific symptoms of brain metastases and (adverse) effects of their treatment are measured by a combination of questionnaires: BN20 and CFQ. The BN20 scoring transforms 20 questions into 11 scales to assess neurological deficits (visual disorder, motor dysfunction, communication deficit), future uncertainty, and disease- and treatment-related symptoms.
The Cognitive Failures Questionnaire (CFQ) is used in ergonomics research to measure behavioural problems associated with attentiveness and memory in everyday life. Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy is completed.Both the total scores of each neurological deficit and cognitive failure and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Change in caregiver reported outcomes: general quality of life | General quality of life will be reported by the questionnaire EQ-5D. The EQ-5D is widely used to measure and evaluate general health status.
Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy of the patient is completed. Both the total score of the questionnaire and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Change in caregiver reported outcomes: depression and anxiety | Depression and anxiety is reported by the HADS. The Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire that has been found to be a reliable instrument for detecting states of anxiety and depression in the setting of hospital outpatient clinic. The HADS questionnaire has seven items each for depression and anxiety subscales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of >8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy of the patient is completed. Both the total score of the questionnaire and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Change in the caregiver burden | The Caregiver Strain Index (CSI) is a tool that can be used to quickly identify families with potential caregiving concerns. It is a 13-question tool that measures strain related to care provision. There is at least one item for each of the following major domains: Employment, Financial, Physical, Social and Time. Positive responses to seven or more items on the index indicate a greater level of strain. This instrument can be used to assess individuals of any age who have assumed the role of caregiver for an older adult.
Baseline, at 1 month, 3 months, and every subsequent 3 months, after initial radiotherapy of the patient is completed. Both the total score of the questionnaire and the individual questions are used in which we look at the difference between the measurement moments. |
Through study completion, an average of 1 year | |
Secondary | Patients coping and personality | Patients are asked to fill out the Utrechtse Coping Lijst (UCL) and the NEO Five-Factor Inventory (NEO-FFI) | Baseline | |
Secondary | Caregiver coping and personality | Caregivers are asked to fill out the Utrechtse Coping Lijst (UCL) and the NEO Five-Factor Inventory (NEO-FFI) | Baseline | |
Secondary | Neurocognitive functioning | The neuro cognitive assessment (NCA) tests that focus on the specific cognitive domains that are most sensitive to the effects of brain irradiation are used for measuring the neurocognitive functioning.
The following domains are tested: general cognitive functioning, memory, language, executive functioning, attention, psychomotor speed, fine motor coordination, visuoconstruction, visuoperception, and social cognition. The test battery takes a maximum of 90 minutes to administer and is based upon international standards |
We are testing this twice: once before radiotherapy and 3 months after radiotherapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05428852 -
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
|
N/A | |
Recruiting |
NCT05559853 -
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
|
||
Recruiting |
NCT05689619 -
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
|
N/A | |
Recruiting |
NCT04197297 -
Brain Imaging Biomarkers in Patients With Brain Metastasis
|
Phase 2 | |
Recruiting |
NCT04397978 -
Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
|
||
Terminated |
NCT04434560 -
Neoadjuvant Immunotherapy in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT05095766 -
Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
|
||
Recruiting |
NCT05012254 -
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05789589 -
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT06280300 -
Multi-disciplinary Care for Brain Metastases
|
N/A | |
Recruiting |
NCT06047379 -
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
|
Phase 1/Phase 2 | |
Completed |
NCT03896555 -
Intrafractional Head Movement During Radiosurgery
|
||
Terminated |
NCT03789149 -
Focal Intraoperative Radiotherapy of Brain Metastases
|
Phase 2 | |
Recruiting |
NCT04343157 -
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
|
Phase 2 | |
Recruiting |
NCT04711824 -
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT05793489 -
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
|
N/A | |
Recruiting |
NCT04461418 -
Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT03818386 -
Radiotherapy of Multiple Brain Metastases Using AGuIX®
|
Phase 2 | |
Active, not recruiting |
NCT05087095 -
Managing Distress in Malignant Brain Cancer
|
N/A | |
Recruiting |
NCT04396717 -
Safety Study of Pritumumab in Brain Cancer
|
Phase 1 |